Question 1 (Kapur, Meltzer, Pani)

How would a disease modification drug affect the course of schizophrenia?

(How might the label of a disease modifying drug read?)
Question 2 (Carpenter, Heinssen)

What should the end points be for Phase 2 or 3 trials of a disease modifying agent for schizophrenia?
Question 3 (Lieberman, Meltzer)

What are the most promising biomarkers for disease modification?

Could a drug be approved that changes something like hippocampal volume without proving that it prevents some form of decline in the following decade?
Question 4 (Carpenter, Heinssen)

How might research and clinical centers for recent onset schizophrenia be organized into research networks?